[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Kuwabara
Yoichi
Y
Komuro
Issei
I
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D017706:Lisinopril / Q000009:adverse effects / Q000627:therapeutic use; D019808:Losartan / Q000009:adverse effects / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000502:physiology; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use; D014633:Valine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007211:Indoles; D013777:Tetrazoles; C052035:trandolapril; D004656:Enalapril; D000068756:Valsartan; D017706:Lisinopril; D014633:Valine; D019808:Losartan; C081643:candesartan